text.skipToContent text.skipToNavigation

인도네시아 고객만을 위한 공지 사항  View details
고객 지원 연락처 정보:
pim.indonesia.contact.title2
Layanan Pengaduan Konsumen

(Business Unit Performance Materials, Sales Support Team)

pim.indonesia.contact.address

Gedung AIA Central, Level 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesia

+62 21 2988 8557

[email protected]

Direktorat Jenderal Perlindungan Konsumen dan Tertib Niaga Kementerian Perdagangan Republik Indonesia
0853 1111 1010

성공! 귀하의 문의가 영업팀에 제출되었습니다.

pim.add.to.wishlist.popup.error

API

API

DKSH는 글로벌 선도 공급업체로부터 고품질 원료의약품(API)을 제공합니다. 다양한 치료 분야에서 제약사의 규제 준수, 안전성 및 일관된 제형 성능을 지원합니다.

API

We have found 26 items.

Filter
Applied FiltersClear all

Physical Form
sustainable
샘플 요청
요청자의 연락처 세부 정보
Full name
Company
Position
Telephone number
Work email address
Shipping address

Thank you. Your request has been sent.

DEXTROSE MONOHYDRATE

덱스트로오스 모노하이드레이트는 유기 화합물입니다. 무색 크리스탈 또는 백색 크리스탈 분말, 무취 및 달콤한. 물에 용해되고 에탄올에 약간 용해됩니다.
CALCIUM ASCORBATE

아스코르브산 칼슘은 흰색에서 약간 황색을 띠며 무취의 결정 또는 결정 분말입니다.
BARCROFT AHMC 0600

위염 & 위식도 역류 질환에 대한 제산제 활성 성분
FEBUXOSTAT

**Product Overview: Febuxostat – A Robust Solution for Gout Management** Refarmed Chemicals presents Febuxostat, a meticulously prepared medication aimed at alleviating the pain and discomfort associated with gout. Made from a refined white powder, Febuxostat stands out in the pharmaceutical industry as a Xanthine Oxidase Inhibitor, crucial for managing hyperuricemia and recurrent gout attacks. Structured to meet corporate expectations, Febuxostat is a testament to Refarmed Chemicals' 30-year expertise in delivering quality generic and branded medications. Manufactured in compliance with strict guidelines, including the Drug Master File (DMF) and certifications such as WC and GMP, this product is a model of reliability and efficacy. Febuxostat's fundamental use is to decrease blood uric acid levels, offering those afflicted with gout a pathway to recovery by preventing acute flare-ups, and mitigating inflammation and pain in the joints. As a white, soluble powder, Febuxostat is highly soluble in DMSO and slightly soluble in methanol and water, simplifying its integration into diverse medical formulations. Clinical trials have informed a standard starting dosage of 40 mg, adjustable up to 80 mg based on individual patient requirements and the severity of symptoms. In its commitment to patient welfare, Refarmed Chemicals underlines potential side effects ranging from nausea and headaches to rashes, ensuring informed usage of Febuxostat. In alignment with our promise of transparency and safety, we advise consulting healthcare professionals for precise diagnotics and treatment plans. Furthermore, users should be attentive to contraindications, noting that Febuxostat is unsuitable for patients with severe liver or kidney disease, or for women who are pregnant or breastfeeding. Refarmed Chemicals' Febuxostat exceeds industry standards with its impressive assay value of 98.0% - 102.0% purity and a precise control of impurities, ensuring that the product meets stringent quality criteria. The company's analytical rigor is reflected in the detailed specification of residual solvents such as Acetone, Ethanol, and Isopropanol. In the journey to deliver improved health outcomes, Refarmed Chemicals' Febuxostat is more than just a medication; it symbolizes our dedication to quality, safety, and corporate responsibility in the global pharmaceutical landscape. [*Note: Product image depicts a detailed specification chart for Febuxostat, reiterating its quality and compositions.*]

 

 

Products still subject to third-party patent protection might be available solely for R&D purposes.

죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
죄송하지만, 이 필드는 비워 둘 수 없습니다.
*필수

문의해 주셔서 감사합니다.

contact.you.lab.product.request.text

Product quantity has been updated.